1. Home
  2. APRE vs GGRP Comparison

APRE vs GGRP Comparison

Compare APRE & GGRP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aprea Therapeutics Inc.

APRE

Aprea Therapeutics Inc.

HOLD

Current Price

$0.90

Market Cap

12.1M

Sector

Health Care

ML Signal

HOLD

Logo The Glimpse Group Inc. Common Stock

GGRP

The Glimpse Group Inc. Common Stock

N/A

Current Price

$0.54

Market Cap

11.8M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
APRE
GGRP
Founded
2006
2016
Country
United States
United States
Employees
N/A
40
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
12.1M
11.8M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
APRE
GGRP
Price
$0.90
$0.54
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$4.10
N/A
AVG Volume (30 Days)
275.5K
48.2K
Earning Date
05-13-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
21.22
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$72.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.55
$0.42
52 Week High
$2.22
$0.68

Technical Indicators

Market Signals
Indicator
APRE
GGRP
Relative Strength Index (RSI) 56.49 47.05
Support Level $0.90 $0.49
Resistance Level $0.98 $0.59
Average True Range (ATR) 0.08 0.05
MACD 0.00 -0.00
Stochastic Oscillator 54.31 24.96

Price Performance

Historical Comparison
APRE
GGRP

About APRE Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.

About GGRP The Glimpse Group Inc. Common Stock

The Glimpse Group Inc is a diversified immersive technology platform company, focused on providing enterprise solutions in virtual reality (VR), augmented reality (AR), and spatial computing. The company operates multiple subsidiaries that develop VR and AR software and services across various industries, including corporate training, education, healthcare, government, defense, marketing, retail, and financial services. It also offers AI-driven spatial computing platforms that support simulations, social VR, behavioral health, and corporate events. The Company reports its revenues in three categories: Software Services, Software License and Software-as-a-Service (SaaS), and Royalty Income, with the majority being from the Software Services category.

Share on Social Networks: